Butterfly Network Inc (BFLY)

$0.82

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Butterfly Network Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 15.42M → 16.51M (in $), with an average increase of 6.6% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -27.36M → -44.12M (in $), with an average decrease of 61.2% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 31.7% return, outperforming this stock by 100.2%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 66.1% return, outperforming this stock by 160.6%

Performance

  • $0.81
    $0.85
    $0.82
    downward going graph

    1.21%

    Downside

    Day's Volatility :4.41%

    Upside

    3.24%

    downward going graph
  • $0.76
    $2.71
    $0.82
    downward going graph

    7.26%

    Downside

    52 Weeks Volatility :71.94%

    Upside

    69.74%

    downward going graph

Returns

PeriodButterfly Network IncSector (Health Care)Index (Russel 2000)
3 Months
-22.7%
-0.7%
0.0%
6 Months
0.63%
6.6%
0.0%
1 Year
-68.48%
3.7%
-1.5%
3 Years
-94.1%
14.0%
-21.8%

Highlights

Market Capitalization
187.3M
Book Value
$1.06
Earnings Per Share (EPS)
-0.65
Wall Street Target Price
3.38
Profit Margin
-202.88%
Operating Margin TTM
-281.03%
Return On Assets TTM
-22.07%
Return On Equity TTM
-49.03%
Revenue TTM
65.9M
Revenue Per Share TTM
0.32
Quarterly Revenue Growth YOY
-13.0%
Gross Profit TTM
39.5M
EBITDA
-124.2M
Diluted Eps TTM
-0.65
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.45
EPS Estimate Next Year
-0.43
EPS Estimate Current Quarter
-0.13
EPS Estimate Next Quarter
-0.12

Analyst Recommendation

Buy
    80%Buy
    20%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Butterfly Network Inc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 312.2%

Current $0.82
Target $3.38

Company Financials

FY19Y/Y Change
Revenue
27.6M
-
Net Income
-99.6M
-
Net Profit Margin
-361.1%
-
FY20Y/Y Change
Revenue
46.3M
↑ 67.68%
Net Income
-162.7M
↑ 63.4%
Net Profit Margin
-351.87%
↑ 9.23%
FY21Y/Y Change
Revenue
62.6M
↑ 35.27%
Net Income
-32.4M
↓ 80.09%
Net Profit Margin
-51.8%
↑ 300.07%
FY22Y/Y Change
Revenue
73.4M
↑ 17.3%
Net Income
-168.7M
↑ 420.61%
Net Profit Margin
-229.9%
↓ 178.1%
FY23Y/Y Change
Revenue
65.9M
↓ 10.21%
Net Income
-133.7M
↓ 20.76%
Net Profit Margin
-202.88%
↑ 27.02%
Q3 FY22Q/Q Change
Revenue
19.6M
↑ 2.1%
Net Income
-54.7M
↑ 52.91%
Net Profit Margin
-279.04%
↓ 92.72%
Q4 FY22Q/Q Change
Revenue
19.0M
↓ 3.24%
Net Income
-33.7M
↓ 38.43%
Net Profit Margin
-177.54%
↑ 101.5%
Q1 FY23Q/Q Change
Revenue
15.5M
↓ 18.47%
Net Income
-33.5M
↓ 0.48%
Net Profit Margin
-216.72%
↓ 39.18%
Q2 FY23Q/Q Change
Revenue
18.5M
↑ 19.46%
Net Income
-28.7M
↓ 14.52%
Net Profit Margin
-155.09%
↑ 61.63%
Q3 FY23Q/Q Change
Revenue
15.4M
↓ 16.58%
Net Income
-27.4M
↓ 4.54%
Net Profit Margin
-177.47%
↓ 22.38%
Q4 FY23Q/Q Change
Revenue
16.5M
↑ 7.1%
Net Income
-44.1M
↑ 61.21%
Net Profit Margin
-267.14%
↓ 89.67%
FY19Y/Y Change
Total Assets
165.1M
-
Total Liabilities
15.3M
-
FY20Y/Y Change
Total Assets
147.2M
↓ 10.87%
Total Liabilities
509.1M
↑ 3222.17%
FY21Y/Y Change
Total Assets
572.0M
↑ 288.59%
Total Liabilities
124.3M
↓ 75.59%
FY22Y/Y Change
Total Assets
417.6M
↓ 26.99%
Total Liabilities
92.2M
↓ 25.8%
FY23Y/Y Change
Total Assets
304.3M
↓ 27.13%
Total Liabilities
84.2M
↓ 8.66%
Q3 FY22Q/Q Change
Total Assets
443.3M
↓ 10.75%
Total Liabilities
99.6M
↓ 9.39%
Q4 FY22Q/Q Change
Total Assets
417.6M
↓ 5.8%
Total Liabilities
92.2M
↓ 7.44%
Q1 FY23Q/Q Change
Total Assets
381.7M
↓ 8.59%
Total Liabilities
85.5M
↓ 7.24%
Q2 FY23Q/Q Change
Total Assets
364.6M
↓ 4.48%
Total Liabilities
86.9M
↑ 1.58%
Q3 FY23Q/Q Change
Total Assets
334.2M
↓ 8.33%
Total Liabilities
76.8M
↓ 11.6%
Q4 FY23Q/Q Change
Total Assets
304.3M
↓ 8.96%
Total Liabilities
84.2M
↑ 9.66%
FY18Y/Y Change
Operating Cash Flow
-69.6M
-
Investing Cash Flow
-1.1M
-
Financing Cash Flow
247.8M
-
FY19Y/Y Change
Operating Cash Flow
-120.4M
↑ 73.08%
Investing Cash Flow
-4.5M
↑ 306.92%
Financing Cash Flow
324.0K
↓ 99.87%
FY20Y/Y Change
Operating Cash Flow
-81.7M
↓ 32.16%
Investing Cash Flow
-2.4M
↓ 46.82%
Financing Cash Flow
54.3M
↑ 16653.09%
FY21Y/Y Change
Operating Cash Flow
-189.2M
↑ 131.56%
Investing Cash Flow
-9.9M
↑ 315.4%
Financing Cash Flow
565.7M
↑ 942.17%
FY22Y/Y Change
Operating Cash Flow
-169.1M
↓ 10.61%
Investing Cash Flow
-93.8M
↑ 850.14%
Financing Cash Flow
2.9M
↓ 99.49%
Q3 FY22Q/Q Change
Operating Cash Flow
-42.0M
↓ 4.47%
Investing Cash Flow
-79.7M
↑ 1027.26%
Financing Cash Flow
2.0M
↑ 1179.87%
Q4 FY22Q/Q Change
Operating Cash Flow
-28.9M
↓ 31.33%
Investing Cash Flow
-2.5M
↓ 96.89%
Financing Cash Flow
137.0K
↓ 93.27%
Q1 FY23Q/Q Change
Operating Cash Flow
-43.3M
↑ 49.87%
Investing Cash Flow
74.9M
↓ 3117.13%
Financing Cash Flow
136.0K
↓ 0.73%
Q2 FY23Q/Q Change
Operating Cash Flow
-26.5M
↓ 38.76%
Investing Cash Flow
-881.0K
↓ 101.18%
Financing Cash Flow
136.0K
↑ 0.0%
Q3 FY23Q/Q Change
Operating Cash Flow
-16.0M
↓ 39.66%
Investing Cash Flow
-1.0M
↑ 18.96%
Financing Cash Flow
92.0K
↓ 32.35%

Technicals Summary

Sell

Neutral

Buy

Butterfly Network Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Butterfly Network Inc
Butterfly Network Inc
-24.13%
0.63%
-68.48%
-94.1%
-96.36%
Stryker Corporation
Stryker Corporation
-5.1%
24.37%
15.51%
30.88%
86.41%
Boston Scientific Corp.
Boston Scientific Corp.
1.07%
34.02%
31.68%
66.24%
93.56%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-6.04%
25.15%
3.43%
-1.49%
47.65%
Abbott Laboratories
Abbott Laboratories
-5.82%
10.82%
1.68%
-14.96%
43.26%
Medtronic Plc
Medtronic Plc
-5.47%
8.78%
-3.15%
-37.3%
-6.1%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Butterfly Network Inc
Butterfly Network Inc
NA
NA
NA
-0.45
-0.49
-0.22
NA
1.06
Stryker Corporation
Stryker Corporation
40.98
40.98
2.92
11.85
0.18
0.07
0.01
48.92
Boston Scientific Corp.
Boston Scientific Corp.
63.66
63.66
1.8
2.25
0.09
0.04
NA
13.16
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
39.15
39.15
5.19
2.76
0.22
0.12
NA
11.06
Abbott Laboratories
Abbott Laboratories
33.4
33.4
5.99
4.59
0.15
0.06
0.02
22.26
Medtronic Plc
Medtronic Plc
25.16
25.16
1.52
5.2
0.08
0.04
0.03
38.95
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Butterfly Network Inc
Butterfly Network Inc
Buy
$187.3M
-96.36%
NA
-202.88%
Stryker Corporation
Stryker Corporation
Buy
$128.5B
86.41%
40.98
15.44%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$100.1B
93.56%
63.66
11.18%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$54.2B
47.65%
39.15
23.36%
Abbott Laboratories
Abbott Laboratories
Buy
$189.5B
43.26%
33.4
14.27%
Medtronic Plc
Medtronic Plc
Buy
$105.2B
-6.1%
25.16
13.0%

Institutional Holdings

  • ARK Investment Management LLC

    6.58%

  • Fosun International Ltd

    5.15%

  • BlackRock Inc

    4.96%

  • Glenview Capital Management LLC

    3.86%

  • Vanguard Group Inc

    3.68%

  • Geode Capital Management, LLC

    1.52%

Corporate Announcements

  • Butterfly Network Inc Earnings

    Butterfly Network Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

butterfly network operates at the cutting edge of multiple engineering and scientific disciplines and strives to bring together world-class talent in computer science, physics, and electrical engineering. the company is privately held and well funded by a small group of extraordinarily successful serial entrepreneurs. the company is in the rare position of being able to focus 100% of its efforts on product and intellectual property development rather than fundraising.

Organization
Butterfly Network Inc
Employees
225
CEO
Dr. Jonathan M. Rothberg Ph.D.
Industry
Healthcare

Discover More

FAQs